The group will start a pivotal trial of samuraciclib following promising second-line results.
ApexOnco Front Page
Recent articles
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
But more detail is awaited, especially on toxicity.
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.
The ESMO regular abstract lift reveals first human datasets for several projects.
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
